These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37335158)

  • 1. Urolithin A exhibits a neuroprotective effect against Alzheimer's disease by inhibiting DYRK1A activity.
    Tu HJ; Su CJ; Peng CS; Lin TE; HuangFu WC; Hsu KC; Hwang TL; Pan SL
    J Food Drug Anal; 2023 Jun; 31(2):358-370. PubMed ID: 37335158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urolithin A improves Alzheimer's disease cognition and restores mitophagy and lysosomal functions.
    Hou Y; Chu X; Park JH; Zhu Q; Hussain M; Li Z; Madsen HB; Yang B; Wei Y; Wang Y; Fang EF; Croteau DL; Bohr VA
    Alzheimers Dement; 2024 Jun; 20(6):4212-4233. PubMed ID: 38753870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of selective dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors and their effects on tau and microtubule.
    Wu YW; HuangFu WC; Lin TE; Peng CH; Tu HJ; Sung TY; Sung TY; Yen SC; Pan SL; Hsu KC
    Int J Biol Macromol; 2024 Feb; 259(Pt 1):129074. PubMed ID: 38163507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
    Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
    J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice.
    Gong Z; Huang J; Xu B; Ou Z; Zhang L; Lin X; Ye X; Kong X; Long D; Sun X; He X; Xu L; Li Q; Xuan A
    J Neuroinflammation; 2019 Mar; 16(1):62. PubMed ID: 30871577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
    Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
    Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Urolithin A on Mitochondrial Parameters in a Cellular Model of Early Alzheimer Disease.
    Esselun C; Theyssen E; Eckert GP
    Int J Mol Sci; 2021 Aug; 22(15):. PubMed ID: 34361099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Potential of Mitophagy-Inducing Microflora Metabolite, Urolithin A for Alzheimer's Disease.
    Jayatunga DPW; Hone E; Khaira H; Lunelli T; Singh H; Guillemin GJ; Fernando B; Garg ML; Verdile G; Martins RN
    Nutrients; 2021 Oct; 13(11):. PubMed ID: 34836000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urolithin A reduces amyloid-beta load and improves cognitive deficits uncorrelated with plaque burden in a mouse model of Alzheimer's disease.
    Ballesteros-Álvarez J; Nguyen W; Sivapatham R; Rane A; Andersen JK
    Geroscience; 2023 Apr; 45(2):1095-1113. PubMed ID: 36576642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease.
    Melchior B; Mittapalli GK; Lai C; Duong-Polk K; Stewart J; Güner B; Hofilena B; Tjitro A; Anderson SD; Herman DS; Dellamary L; Swearingen CJ; Sunil KC; Yazici Y
    Aging Cell; 2019 Oct; 18(5):e13000. PubMed ID: 31267651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
    García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
    Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?
    Smith B; Medda F; Gokhale V; Dunckley T; Hulme C
    ACS Chem Neurosci; 2012 Nov; 3(11):857-72. PubMed ID: 23173067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
    Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of miR-26a-5p Suppresses Tau Phosphorylation and Aβ Accumulation in the Alzheimer's Disease Mice by Targeting DYRK1A.
    Liu Y; Wang L; Xie F; Wang X; Hou Y; Wang X; Liu J
    Curr Neurovasc Res; 2020; 17(3):241-248. PubMed ID: 32286945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.
    Kawakubo T; Mori R; Shirotani K; Iwata N; Asai M
    Biol Pharm Bull; 2017; 40(3):327-333. PubMed ID: 28250274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dyrk1A-mediated phosphorylation of Presenilin 1: a functional link between Down syndrome and Alzheimer's disease.
    Ryu YS; Park SY; Jung MS; Yoon SH; Kwen MY; Lee SY; Choi SH; Radnaabazar C; Kim MK; Kim H; Kim K; Song WJ; Chung SH
    J Neurochem; 2010 Nov; 115(3):574-84. PubMed ID: 20456003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urolithin A protects dopaminergic neurons in experimental models of Parkinson's disease by promoting mitochondrial biogenesis through the SIRT1/PGC-1α signaling pathway.
    Liu J; Jiang J; Qiu J; Wang L; Zhuo J; Wang B; Sun D; Yu S; Lou H
    Food Funct; 2022 Jan; 13(1):375-385. PubMed ID: 34905594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
    Ferrer I; Barrachina M; Puig B; Martínez de Lagrán M; Martí E; Avila J; Dierssen M
    Neurobiol Dis; 2005 Nov; 20(2):392-400. PubMed ID: 16242644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KAT7/HMGN1 signaling epigenetically induces tyrosine phosphorylation-regulated kinase 1A expression to ameliorate insulin resistance in Alzheimer's disease.
    Lu QS; Ma L; Jiang WJ; Wang XB; Lu M
    World J Psychiatry; 2024 Mar; 14(3):445-455. PubMed ID: 38617985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
    Asai M; Kawakubo T; Mori R; Iwata N
    Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.